Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone973-605-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.16 million
Profitability
Miscellaneous
Employees346
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Immunomedics (NASDAQ:IMMU) Frequently Asked Questions
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.06. The biopharmaceutical company earned $0.50 million during the quarter, compared to analyst estimates of $4.27 million. Immunomedics had a negative return on equity of 89.31% and a negative net margin of 12,701.21%. Immunomedics's revenue was down 61.5% compared to the same quarter last year. View Immunomedics' Earnings History.
When is Immunomedics' next earnings date?
What price target have analysts set for IMMU?
9 Wall Street analysts have issued 1-year price objectives for Immunomedics' stock. Their predictions range from $18.00 to $38.00. On average, they expect Immunomedics' share price to reach $28.00 in the next year. This suggests a possible upside of 54.0% from the stock's current price. View Analyst Price Targets for Immunomedics.
What is the consensus analysts' recommendation for Immunomedics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.
Has Immunomedics been receiving favorable news coverage?
News articles about IMMU stock have been trending somewhat negative on Tuesday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immunomedics earned a news impact score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Are investors shorting Immunomedics?
Immunomedics saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 29,745,537 shares, an increase of 4.3% from the February 15th total of 28,516,305 shares. Based on an average trading volume of 2,762,869 shares, the days-to-cover ratio is currently 10.8 days. Approximately 17.4% of the shares of the company are sold short. View Immunomedics' Current Options Chain.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and Riot Blockchain (RIOT).
What other stocks do shareholders of Immunomedics own?
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
- Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
- Mr. Scott A. Canute MBA, Exec. Director (Age 58)
- Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
- Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)
Who are Immunomedics' major shareholders?
Immunomedics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.64%), FMR LLC (4.32%), American Century Companies Inc. (1.64%), RA Capital Management LLC (1.59%), Foresite Capital Management III LLC (1.42%) and Jennison Associates LLC (1.30%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.
Which institutional investors are selling Immunomedics stock?
IMMU stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Lord Abbett & CO. LLC, Victory Capital Management Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, RA Capital Management LLC, MetLife Investment Advisors LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Immunomedics.
Which institutional investors are buying Immunomedics stock?
IMMU stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Norges Bank, American Century Companies Inc., Polar Capital LLP, Sectoral Asset Management Inc, BlackRock Inc., Tekla Capital Management LLC and Jennison Associates LLC. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.
How do I buy shares of Immunomedics?
Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of IMMU stock can currently be purchased for approximately $18.18.
How big of a company is Immunomedics?
Immunomedics has a market capitalization of $3.46 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 346 workers across the globe.
What is Immunomedics' official website?
How can I contact Immunomedics?
Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]
MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
